Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
5 Top Stock Trades for Thursday: TGT, LOW, V, BMRN, NVDA
05:01pm, Wednesday, 19'th Aug 2020
Nvidia, BioMarin, Visa, Lowe's and Target were our top stock trades. That said, let's look at what the charts are telling us now.
Nasdaq Falls Off Record Levels; Momenta, BioMarin Head in Opposite Directions
04:36pm, Wednesday, 19'th Aug 2020
The Fed spoiled the party for the stock market.
BioMarin Stock Slumps After FDA’s Surprise Rejection of a Hemophilia Gene Therapy
04:19pm, Wednesday, 19'th Aug 2020
Shares of (BMRN) plunged Wednesday morning, after the company said federal regulators had declined its application to market the first gene therapy for hemophilia. Wall Street has largely rated the
Two Surprising FDA Rejections Raise Alarms for Biotech Investors
04:00pm, Wednesday, 19'th Aug 2020
(Bloomberg) -- The Food and Drug Administration’s rejection of a pair of medicines that Wall Street expected to sail by regulators raised concerns that other upcoming drug decisions could meet a sim
Looking Into Biomarin Pharmaceutical's Return On Capital Employed
03:35pm, Wednesday, 19'th Aug 2020
Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q2 sales of $429.49 million. Earnings fell to a loss of $38.44 million, resulting in a 188.15% decrease from last quarter. Biomarin Pharmaceutical earne
U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive
03:34pm, Wednesday, 19'th Aug 2020
BioMarin shares fell 31%, or $37, to $81.54 in morning trading. There are about 16,000 patients in the United States with hemophilia A in which they are missing the factor VIII clotting protein. It
BioMarin Shares Slammed After Hemophilia A Gene Therapy Stumbles At FDA
03:08pm, Wednesday, 19'th Aug 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares were plunging Wednesday after a negative outcome for a binary event.
Here's Why BioMarin Pharmaceutical Plummeted Today
02:19pm, Wednesday, 19'th Aug 2020
The biotech is going to have to wait awhile to get its hemophilia A treatment approved by the FDA.
BioMarin Receives FDA Rejection for Hemophilia Gene Therapy
02:10pm, Wednesday, 19'th Aug 2020
The decision puts a major dent into BioMarin's effort to come up with one-time gene therapies for the disease.
FDA Rejects BioMarin's Hemophilia Gene Therapy
02:09pm, Wednesday, 19'th Aug 2020
It's bad news for hemophilia A sufferers in the U.S., and for the company's shareholders.
BioMarin's stock falls 27% after FDA asks for additional data about experimental hemophilia A drug
01:42pm, Wednesday, 19'th Aug 2020
Shares of BioMarin Pharmaceutical Inc. undefined tumbled 27.6% in trading on Wednesday after the company said it had received a complete response letter from...
BioMarin's stock falls 27% after FDA asks for additional data about experimental hemophilia A drug
01:42pm, Wednesday, 19'th Aug 2020
Shares of BioMarin Pharmaceutical Inc. tumbled 27.6% in trading on Wednesday after the company said it had received a complete response letter from the Food and Drug Administration for its experiment
BioMarin Sinks as FDA Approval Pushed Until At Least 2022
12:33pm, Wednesday, 19'th Aug 2020
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) slumped more than 36% on Wednesday after the U.S. Food and Drug Administration rejected its gene therapy for hemophilia A. The FDA cited the need for longer-
U.S. FDA declines to approve Biomarin's gene therapy for bleeding disorder
12:07pm, Wednesday, 19'th Aug 2020BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
12:00pm, Wednesday, 19'th Aug 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the Company's Biologics License Application (BLA
